Market Research Logo

Global Dementia and Movement Disorder Treatment Market 2017-2021

Global Dementia and Movement Disorder Treatment Market 2017-2021

About Dementia and Movement Disorder Treatment

Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and personality changes, difficulty in performing activities, loss of memory, and aphasia. Dementia can be classified into different types, based on the parts of brain affected. Among these types, Alzheimer’s disease is the most common type of dementia.

Technavio’s analysts forecast the global dementia and movement disorder treatment market to grow at a CAGR of 4.48% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global dementia and movement disorder treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Dementia and Movement Disorder Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Eisai
  • Novartis
  • Teva Pharmaceutical Industries
Other prominent vendors
  • Amgen
  • Pfizer
  • UCB
  • H. Lundbeck
  • F. Hoffmann-La Roche
  • Eli Lilly
Market driver
  • Need for disease modifying drugs (DMDs)
  • For a full, detailed list, view our report
Market challenge
  • Social stigma associated with dementia
  • For a full, detailed list, view our report
Market trend
  • Emergence of biomarkers
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Dementia and Movement Disorder Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global dementia and movement disorder treatment market: Allergan, Eisai, Novartis, and Teva Pharmaceutical Industries.

Other Prominent Vendors in the market are: Amgen, Pfizer, UCB, H. Lundbeck, F. Hoffmann-La Roche, and Eli Lilly.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of biomarkers. The global DAMD market is primarily dominated by MAO inhibitors, AChE inhibitors, and glutamate inhibitors. Use of these drugs for the treatment of different types of dementia such as Lewy body dementia and movement disorders such as Parkinson’s disease indicates that these diseases have the same pathological conditions.”

According to the report, one driver in the market is need for disease modifying drugs. The treatment for dementia is currently dominated by therapeutic approaches that are focused on providing symptomatic relief; drugs indicated for the treatment of various types of dementia and movement disorders only treat symptoms and not the underlying cause of the disease. These drugs either belong to the class of anticholinesterase inhibitors or modulate the activity of glutamate on the nervous system. Anticholinesterase inhibitors act by reversible or irreversible inhibition of cholinesterase responsible for the depletion of ACh from the synaptic cleft.

Further, the report states that one challenge in the market is social stigma associated with dementia. Dementia is a neurological condition, characterized by poor cognitive functions, impaired social and occupational functioning, and diminished memory. It is perceived negatively in different parts of the world; the perception varies from it being viewed as a natural consequence of aging or in worse cases inadvertently linked to archaic beliefs. This, in turn, has a negative impact on those with dementia as they often refrain from reporting their symptoms to healthcare providers, leading to low diagnostic rates, thus hampering the market growth. In some parts of the world, public disclosure of such symptoms triggers negative reactions from family and friends leading to a kind of social isolation.

Companies Mentioned

Allergan, Eisai, Novartis, Teva Pharmaceutical Industries, Amgen, Pfizer, UCB, H. Lundbeck, F. Hoffmann-La Roche, and Eli Lilly.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Functions of brain affected by dementia
      • Table Types of Alzheimer's disease
  • Dementia: An overview
    • Dementia
      • Table Cognitive impairment in dementia
    • Epidemiology of disease
    • Types of dementia
      • Table Types of dementia
      • Table Types of dementia by prevalence rate 2006
    • Medical interventions to treat dementia
    • Parkinson's disease and dementia
      • Table Vendor initiative in DAMD treatment market
  • Movement disorder: An overview
    • Movement disorders
      • Table Types of movement disorders
      • Table Insufficient movement disorders
      • Table Excessive movement disorders
    • Cause of movement disorders
      • Table Cause of movement disorder
  • Market landscape
    • Market overview
      • Table Market segmentation by drug class 2016
      • Table Market snapshot: Global DAMD treatment market
    • Market size and forecast
      • Table Global DAMD treatment market 2016-2021 ($ millions)
      • Table Opportunity analysis of global DAMD treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline
    • Table Pipeline landscape based on number of molecules 2016
    • Table Alzheimer's disease: Key clinical trials
    • Table Huntington's disease: Key clinical trials
    • Table Parkinson's disease: Key clinical trials
  • Segmentation by drug class
    • Table Global DAMD treatment market by drug class
    • Table Global DAMD treatment market by drug-class 2016
    • Global DAMD treatment market by MAO inhibitors
      • Table Global DAMD treatment market by MAO inhibitors 2016-2021 ($ millions)
    • Global DAMD treatment market by AchE inhibitors
      • Table Global DAMD treatment market by AChE inhibitors 2016-2021 ($ millions)
    • Global DAMD treatment market by glutamate inhibitors
      • Table Global DAMD treatment market by glutamate inhibitors 2016-2021 ($ millions)
    • Global DAMD treatment market by others
      • Table Global DAMD treatment market by others 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Global DAMD treatment market by geography 2016 and 2021
    • Table Global DAMD treatment market by geography 2016-2021 ($ millions)
    • Table Global DAMD treatment market by geography 2016-2021
    • Table DAMD treatment market scenario in different regions
    • DAMD treatment market in Americas
      • Table Market scenario in Americas
      • Table DAMD treatment market in Americas 2016-2021 ($ millions)
    • DAMD treatment market in EMEA
      • Table Market scenario in EMEA
      • Table DAMD treatment market in EMEA 2016-2021 ($ millions)
    • DAMD treatment market in APAC
      • Table Market scenario in APAC
      • Table DAMD treatment market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Prevalence rate of dementia 2006
      • Table Geriatric population analysis by geography in 2000 and estimates for 2030
      • Table Death rate per 100,000 in US population due to Alzheimer's disease 2010-2014
    • Market challenges
      • Table Revenue erosion of Aricept after loss of exclusivity
  • Market trends
    • Emergence of biomarkers
    • Growth of gene therapy to reverse cognitive decline associated with Alzheimer's disease
    • Advances in biomedical science
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global DAMD treatment market 2016
  • Key vendor analysis
    • Allergan
      • Table Allergan: Key highlights
      • Table Allergan: Strength assessment
      • Table Allergan: Strategy assessment
      • Table Allergan: Opportunity assessment
    • Eisai
      • Table Eisai: Key highlights
      • Table Eisai: Strength assessment
      • Table Eisai: Strategy assessment
      • Table Eisai: Opportunity assessment
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Teva Pharmaceutical Industries
      • Table Teva Pharmaceutical Industries: Pipeline molecules for treatment of neurodegenerative disorders
      • Table Teva Pharmaceutical Industries: Key highlights
      • Table Teva Pharmaceutical Industries: Strength assessment
      • Table Teva Pharmaceutical Industries: Strategy assessment
      • Table Teva Pharmaceutical Industries: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report